tradmap

ALEC Alector, Inc.

$1.74 +10.83%

Healthcare · Biological Products, (No Diagnostic Substances)

Alector, Inc. (ALEC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $193 million. Shares last traded at $1.74, 48.7% below their 52-week high. Over the past year the stock is up 14.5%. Net profit margin is -679.5%, below the peer median of 6.3%. Revenue declined 79.1% year over year.

Market Cap
$193M
Shares Out
111.0M
EPS (TTM)
$-2.38
P/E Ratio
P/S Ratio
9.18
P/B Ratio
18.61
Dividend / Share
Dividend Yield
52-Week High
$3.40
52-Week Low
$1.09
Volume
41,617
Avg Vol (3m)
44,288.952

Performance

1W
+11.54%
1M
-17.92%
3M
-15.53%
6M
+25.63%
YTD
+14.47%
1Y
+14.47%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
43.95
SMA (50)
$2.15
SMA (200)
$2.07
Price vs SMA50
-18.98%
Price vs SMA200
-15.77%
ATR (14)
$0.14

Financials

Revenue
$21M
Net Income
$-143M
Gross Margin
Operating Margin
-741.3%
Net Margin
-679.5%
Return on Equity
-1377.4%
Return on Assets
-59.6%
Current Ratio
5.25
Debt / Equity
0.80
Revenue Growth (YoY)
-79.1%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.21 2026-05-07
FY 2025 $-1.39 2026-02-25
Q3 2025 $-1.05 2025-11-06
Q2 2025 $-0.71 2025-08-07
Q1 2026 $-0.41 2026-05-07
FY 2025 $-1.23 2026-02-25

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ALEC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
9.18 / 5.21 med
+76% premium
Net margin vs peers
-679.5% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.